Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Tryptophan hydroxylase 2 (TPH2) is an enzyme that catalyzes the rate-limiting step in the biosynthesis of serotonin in the central nervous system. It is a member of the aromatic amino acid hydroxylase superfamily and is distinct from TPH1, which operates primarily in peripheral tissues. Mutations or polymorphisms in TPH2 are associated with various psychiatric disorders including depression, anxiety disorders, aggression-related behaviors, obsessive-compulsive disorder (OCD), schizophrenia, catalepsy, and other stress-related conditions.
Pharmacological chaperones (for stabilizing mutant forms); Inhibitors (for reducing excess activity)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Tryptophan Hydroxylase 2 (None).